EN PL
 
EN PL
Bieżący numer
Archiwum
Online first
O czasopiśmie
Dla autorów
Książki i Konferencje
1/2009 vol. 47
Pobierz cytowanie
PRACA PRZEGLĄDOWA
Nefrogenne włóknienie układowe
Olga Borys
,
 
Maria Majdan
,
 
Ewa Wielosz
,
 
Iwona Żychowska
 
 
 
Więcej
Ukryj
 
Data publikacji online: 01-04-2009
 
 
Reumatologia 2009;47(1):34-38
 
Artykuł (PDF)
Referencje (37)
 
SŁOWA KLUCZOWE
nefrogenne włóknienie układowe
przewlekła choroba nerek
gadolin
 
STRESZCZENIE
Rozwój nowych technik terapeutycznych i diagnostycznych pozwala na utrzymanie przy życiu wielu chorych, jednocześnie jednak niesie ze sobą ryzyko rozwoju zupełnie nowych schorzeń, dotychczas nieobserwowanych w patologii ludzkiej. Należy do nich nefrogenne włóknienie układowe, choroba przypominająca twardzinę układową, przebiegająca z zajęciem skóry i narządów wewnętrznych; nieleczona szybko prowadzi do zgonu chorego. Nefrogenne włóknienie układowe rozwija się u osób w zaawansowanym okresie przewlekłej choroby nerek. Stwierdzono zależność między podaniem radiologicznych środków kontrastowych zawierających gadolin a rozwojem tego schorzenia. Wczesna diagnostyka oraz postępowanie prewencyjne mogą zapobiegać rozwojowi choroby. Z tego powodu konieczne jest uwrażliwienie środowiska lekarskiego na ten problem.
 
REFERENCJE (37)
1.
Cowper SE. Nephrogenic systemic fibrosis: the nosological and conceptual evolution of nephrogenic fibrosing dermopathy. Am J Kid Dis 2005; 46: 763-765.
Google Scholar
 
 
2.
Othersen JB, Maize JC, Woolson RF, Budisavljevic MN. Nephrogenic systemic fibrosis after exposure to gadolinium in patients with renal failure. Nephrol Dial Transplant 2007; 22: 3179-3185.
Google Scholar
 
 
3.
Cowper SE, Robin HS, Steinberg SM, et al. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 2000; 356: 1000-1001.
Google Scholar
 
 
4.
Marckman P. An epidemic outbreak of nephrogenic systemic fibrosis in a Danish hospital. Eur J Rad 2008; 66: 187-190.
Google Scholar
 
 
5.
Nortier JL, del Marmol V. Nephrogenic systemic fibrosis – the need for a multidisciplinary approach. Nephrol Dial Transplant 2007; 22: 3097-3101.
Google Scholar
 
 
6.
Marckmann P, Skov L, Rossen K, Thomsen HS. Clinical manifestation of gadodiamide-related nephrogenic systemic fibrosis. Clin Nephrol 2008; 9: 161-168.
Google Scholar
 
 
7.
Todd DJ, Kagan A, Chibnik LB, Kay J. Cutaneous changes of nephrogenic systemic fibrosis predict early mortality and are associated with gadolinium exposure. Arthritis Rheum 2007; 56: 3433-3441.
Google Scholar
 
 
8.
Kay J. What causes nephrogenic systemic fibrosis? Dialysis Transplant 2008; 3: 95-98.
Google Scholar
 
 
9.
Cowper SE, Bucala R. Nephrogenic fibrosing dermopathy: suspect identified, motive unclear. Am J Dermatopathol 2003; 25: 358.
Google Scholar
 
 
10.
Daram SR, Cortese CM, Bastani B. Nephrogenic Dermopathy/Nephrogenic Systemic Fibrosis: report of a new case with literature review. Am J Kidney Dis 2005; 46: 754-759.
Google Scholar
 
 
11.
Cowper SE, Su LD, Bhawan J, et al. Nephrogenic fibrosing dermopathy. Am J Dermatopathol 2001; 23: 383-393.
Google Scholar
 
 
12.
Levine JM, Taylor RA, Elman LB, et al. Involvement of skeletal muscle in dialysis-associated systemic fibrosis (nefrogenic fibrosing dermopathy). Muscle Nerve 2004; 30: 569-577.
Google Scholar
 
 
13.
Gibson SE, Farver CF, Prayson RA. Multiorgan involvement in nephrogenic fibrosing dermopathy: an autopsy case and review of the literature. Arch Pathol Lab Med 2006; 130: 209-212.
Google Scholar
 
 
14.
Ting WW, Stone MS, Madison KC, Kurtz K. Nephrogenic fibrosing dermopathy with systemic involvement. Arch Dermatol 2003; 139: 903-906.
Google Scholar
 
 
15.
Shin K, Granter SR, Coblyn JS, Gupta S. Progressive arm and leg stiffness in a patient with chronic renal impairment. Nat Clin Pract Reumatol 2008; 4: 557-562.
Google Scholar
 
 
16.
Jiménez SA, Artlett CM, Sandorfi N, et al. Dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy): study of inflammatory cells and transforming growth factor beta-1 expression in affected skin. Arthritis Rheum 2004; 50: 2660-2666.
Google Scholar
 
 
17.
Marckman P, Skov L, Rossen K, et al. Case control study of gadodiamid-related nephrogenic systemic fibrosing. Nephrol Dial Transplant 2007; 22: 3174-3178.
Google Scholar
 
 
18.
Cowper SE. Nephrogenic fibrosing dermopathy: The first 6 years. Curr Opin Rheumatol 2003; 15: 785-790.
Google Scholar
 
 
19.
Swaminathan S, Ahmed J, McCarthy RC, et al. Nephrogenic fibrosing dermopathy and high-dose erythropoietin therapy. Ann Intern Med 2006; 145: 234-235.
Google Scholar
 
 
20.
Grobner T, Prischl FC. Patient characteristics and risk factors for nephrogenic systemic fibrosis following gadolinium exposure. Semin Dial 2008; 21: 135-9.
Google Scholar
 
 
21.
Mallo M, Abt P, Kashyap R, et al. Nephrogenic systemic fibrosis among liver transplant recipients: a single institution experience and topic update. Am J Transplant 2006; 6: 2212-2221.
Google Scholar
 
 
22.
Grobner T. Gadolinium – a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006; 21: 1104-1108.
Google Scholar
 
 
23.
Marckmann P, Skov L, Rossen K, et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 2006; 17: 2359-2362.
Google Scholar
 
 
24.
Deo A, Fogel M, Cowper SE. Nephrogenic systemic fibrosis: a population study examination the relationship of disease development to gadolinium exposure. Clin J Am Soc Nephrol 2007; 2: 264-267.
Google Scholar
 
 
25.
Sadowski EA, Bennett LK, Chan MR, et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 2007; 243: 148-157.
Google Scholar
 
 
26.
Broome DR, Girguis MS, Baron PW, et al. Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. AJM Am J Roentgenol 2007; 188: 586-592.
Google Scholar
 
 
27.
Boyd AS, Zic JA, Abraham JL. Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol 2007; 56: 27-30.
Google Scholar
 
 
28.
High WA, Ayers RA, Chandler J, et al. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 2007; 56: 21-26.
Google Scholar
 
 
29.
Bellin MF, Van Der Molen AJ. Extracellular gadolinium-based contrast media: an overview. Eur J Radiol 2008; 66: 160-167.
Google Scholar
 
 
30.
Broome DR. Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: a summary of the medical literature reporting. Eur J Rad 2008; 66: 230-234.
Google Scholar
 
 
31.
Morcos SK, Thompsen HS. Nephrogenic systemic fibrosis: more questions and some answers. Nephron Clin Pract 2008; 110: 24-32. .
Google Scholar
 
 
32.
Baron PW, Cantos K, Hillebrand DJ, et al. Nephrogenic fibrosing dermopathy after liver transplantation successfully treated with plasmapheresis. Am J Dermathol 2003; 25: 204-209.
Google Scholar
 
 
33.
Gilliet M, Cozzio A, Burg G, Nestle FO. Successfull treatment of three cases of nephrogenic fibrosing dermopathy with extracorporeal photopheresis. Br J Dermatol 2005; 152: 531-536.
Google Scholar
 
 
34.
Schmook T, Budde K, Urich C, et al. Successful treatment of nephrogenic fibrosing dermopathy in a kidney transplant recipient with photodynamic therapy. Nephrol Dial Transplant 2005; 20: 220-222.
Google Scholar
 
 
35.
Fazeli A, Lio PA, Liu V. Nephrogenic fibrosing dermopathy: are ACE inhibitors the missing link? Arch Dermatol 2004; 140: 1401.
Google Scholar
 
 
36.
Chung HJ, Chung KY. Nephrogenic fibrosing dermopathy: response to high – dose intravenous immunoglobulin. Br J Dermatol 2004; 150: 596-597.
Google Scholar
 
 
37.
Kay J. Imatinib mesylate treatment improves skin changes of nephrogenic systemic fibrosis. Arthritis Rheum 2008; 58: 2543-2548.
Google Scholar
 
 
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Udostępnij
Wyślij mailem
Indeksy
 
Indeks słów kluczowych
Indeks dziedzin
Indeks autorów
eISSN:2084-9834
ISSN:0034-6233
Journals System - logo
© 2006-2024 Journal hosting platform by Bentus
Scroll to top